The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...

The Company reported a net loss of approximately $8.4 million, or $0.25 per share, for the three months ended September 30, ...

A 61-year-old man allegedly stabbed Sunday night by his 26-year-old son in Pearl City told police his son suffers from ...

Psychedelics have been growing in popularity across North America for recreational and therapeutic use, with celebrities like ...

Among individuals with schizophrenia, the risk for natural-cause mortality was increased in those with reduced cognitive functioning.

A new study links hallucinogen-related emergency department visits to a 21-fold increased risk of schizophrenia compared to ...

People who visited emergency departments for use of psychedelics had higher likelihood of developing schizophrenia, study ...

The research, led by Dr. Daniel Myran, a Canada Research Chair in Social Accountability at the University of Ottawa, followed ...

Researchers conducted a cohort study to assess the predictive value of plasma MMP9 in antipsychotic treatment response among patients with schizophrenia.

Even after controlling for a person’s existing substance use and mental health disorders, there remained a 3.5-fold increased ...

Individuals with emergency department visits involving hallucinogen use are at high risk of developing schizophrenia, ...

New research highlights neuroglia (or glia cells) as critical players in mental health, potentially influencing conditions like depression and schizophrenia.